Dr. Hartmut Juhl is an entrepreneur, surgical oncologist, and world-renowned researcher dedicated to the science of tissue quality and its application to precision medicine in cancer diagnostics and therapeutics. Hartmut holds a professorship at the Medical Faculty of Hamburg University, is an adjunct professor at the Lombardi Cancer Center of Georgetown University, and has served as an advisor to the U.S. National Cancer Institute on matters of tissue quality for clinical and research applications.
From 1987 to 1992, he worked as a research associate and resident at the Hamburg-Eppendorf Surgical University Clinic. In 1992 he moved to the Surgical Clinic of the Christians Albrecht University in Kiel, where he worked as a surgical oncologist and, simultaneously, led a molecular oncology research group until 1998. He became a specialist in general surgery (“Facharzt”) in 1995. In 1999, he became Associate Professor at the Lombardi Cancer Center of Georgetown University.
In 2002, Hartmut became co-founder of Indivumed GmbH in Hamburg and was awarded the “Hamburg Foundation Prize” in the category of “Founders of new Businesses” in 2003, as well as the German Foundation Prize in the category of “New Visionary” in 2005.
In 2004, he founded Indivumed Inc, a subsidiary of Indivumed GmbH, to cover the US business. In 2008, Hartmut initiated the foundation of Inostics GmbH, a subsidiary of Indivumed GmbH, jointly owned with scientists from Johns Hopkins University, Baltimore, Maryland.
In 2011 Hartmut founded IndivuTest, a specialized diagnostic lab to individualize cancer therapy, as a subsidiary of Indivumed. He successfully closed six rounds of financing to build up and grow Indivumed GmbH and its subsidiaries, respectively, and in 2013, he successfully managed the sale of Inostics GmbH to Sysmex Corporation.
Hartmut studied medicine at the Hamburg-Eppendorf University Clinic from 1979 to 1986. He received his doctorate of medicine (Dr. med.) in 1989, and his “Habilitation” in Surgical Oncology in 1996.
Andrew Deubler brings to Indivumed 25 years of administrative and business experience negotiating and securing research and clinical care collaborations between industry, government, academia, and healthcare systems around the world.
Prior to coming to Indivumed, Andrew served as executive vice president of Geisinger Health System, one of the largest integrated rural health care systems in the US, where he led a team that successfully negotiated one of the country’s largest genomics collaborations between a clinical care system and industry.
Andrew also served as vice president at Georgetown University Medical Center, where he managed operations, strategic planning, and launched the medical center’s first industry relations office. He served nearly a decade at the University of Rochester and University of Rochester Medical Center as vice president, responsible for securing extramural funding to support the expansion of the University’s academic and research infrastructure. In total, Andrew has secured more than $400,000,000 in public and private funding to advance cutting-edge research and state-of-the-art clinical care, while fostering successful governmental and commercial collaborations to advance innovation.
Andrew holds a bachelor’s degree from Hartwick College and a master’s degree from George Washington University.
Michael Gutsmann brings over 25 years of administrative and business experience in scaling companies and implementing value-driving based on a systematic approach paired with clear processes to Indivumed.
Prior to joining Indivumed, Michael served as the CFO or COO for companies like Bigpoint, Dreamlines, AOL, Blockhouse Group, and Iconmedialab. At Bigpoint and Dreamlines he implemented system-based processes which became an essential part of the value chain, forming the backbone for the tremendous growth that they experienced. In total, he secured more than €700 million in funding for both companies.
Michael started his career at Jungheinrich, a forklift company, before moving to Staples as head of controlling, before joining Iconmedialab. He holds a master’s degree from Hamburg University.
Dr. Dietrich K Hauffe brings over 25 years of business and management expertise in life sciences, biotechnology, diagnostics und applied markets to Indivumed.
Dr. Hauffe earned his Ph.D. in Biochemistry and Molecular Biology at the University of Cologne and the Max-Planck-Institute of Plant Breeding, Cologne. He continued his academic career at the University of British Columbia, Vancouver, Canada, and in Freiburg, Germany.
Global management characterizes his professional career: this includes value-creating P&L responsibility, innovative product portfolio development and go-to-market strategy, organizational leadership, matrix and line process development, as well as by creating effective sales and support functions to enable the highest returns. At globally renowned technology companies such as DIONEX, QIAGEN, and BRUKER, his assignments in leadership teams and executive boards grew while increasing in responsibility.
He spent several years in the U.S., received multiple awards, and most recently, was engaged in consulting for global companies based in North America and Europe.
In his position as Chief Commercial Officer at Indivumed, Dr. Hauffe is responsible for all commercial operations, including global sales and support, product development, product portfolio management, and marketing communications.
Frank Clausen brings to Indivumed more than 25 years of execution, administrative, and leadership experience negotiating and securing cross-departmental collaborations between healthcare business and internal IT.
Prior to coming to Indivumed, for 20 years he served as director of IT with Sysmex Europe GmbH, Europe’s top laboratory diagnostics and healthcare company, and the global leader in hematology diagnostics and service. Frank has expansive experience with various IT systems and Japanese and American inter-cultural exchange. As the project manager, he was part of the team responsible for the implementation of SAP R/3, a Datawarehouse, Microsoft SharePoint, and self-developed CRM solution.
He holds a degree from a Hamburg business school and a foreign large business apprenticeship.
Dr. Susanne Arbogast brings to Indivumed more than ten years of experience in implementing research and development programs with a strong focus on (immuno-) oncology projects. This is paired with her extensive expertise in global management of the interface between pharma and diagnostics, as well as a broad external scientific network.
Susanne is a full board certified anatomical and surgical pathologist. She studied medicine at the University of Freiburg, Harvard Medical School, and the LMU Munich, receiving her doctorate of medicine (Dr. med.) in 1992.
She worked at the Pathology Institute of the LMU Munich for more than 15 years, most recently as assistant medical director. In 2007, Susanne joined Roche as Global Head of Pathology and Tissue Biomarkers, responsible for setting up and running a global team (Europe/US/China) to drive all tissue-related discovery and clinical biomarker programs to enable personalized health care.
PD Dr. Peter Frommolt brings more than ten years of experience in the field of medical genome research to his position as Indivumed’s Global Head of Bioinformatics and Data Management.
As a scientist, he has worked at the Institute of Medical Statistics, Informatics and Epidemiology, the Cologne Center for Genomics, and acted as Head of Bioinformatics Core Facility, in the CECAD Research Center at the University Hospital of Cologne, Germany. His work focused on the development and operation of data analysis systems for high-throughput molecular data in core facility environments. Before joining the Indivumed team, he received a call to the Goethe University Frankfurt am Main, Germany, in 2017.
Peter has a background in mathematics and holds a doctoral degree as well as the postdoctoral lecturing qualification (habilitation) for medical bioinformatics from the University of Cologne.
Dr. Heinz Joachim List’s experience combines more than 10 years of hands-on cancer research and some 15 years of negotiating and securing sales and business contracts with pharma, biotech, and diagnostics firms.
Heinz Joachim has dedicated his entire career to cancer research and to bringing its advances to the patient. His focus is on building unique, innovative solutions and resources to support the development of individualized cancer therapies and diagnostics for advancing personalized medicine. Prior to joining Indivumed, he held positions as a post-doctoral researcher and laboratory manager at Georgetown University Medical Center. As a researcher, he published various peer-reviewed articles and book chapters.
Having been with Indivumed since its founding, Heinz Joachim has driven the company’s growing commercial international business operations. Over time he has built and led Indivumed’s finance, licensing, sales, and global business development activities. Under his lead, many successful relationships with international leaders in the pharma and diagnostics industry have been established.
Heinz Joachim received his Ph.D. in Chemistry from the Technical University of Darmstadt, Germany. In 2002, he earned a Master of Business Administration (MBA) degree from Johns Hopkins University in Baltimore, MD, USA.
Gudrun Niewel brings 30 years of professional experience in finance to Indivumed.
Before joining Indivumed in November 2008, she worked in several controlling and management positions in various industry segments. Since 1991 she has worked in an international business environment. Gudrun was the corporate controller of a German biotechnology company for nine years, where she supported its IPO and was responsible for the primary headquarters as well as its subsidiaries.
Gudrun holds a master’s degree in Business Administration from Westfälische Wilhelms-University Münster. She also completed a stipendiary postgraduate study focused on small and medium-sized business at ITW Berlin.
Dr. Hans Vanhooren has worked in the life sciences industry for over 20 years, with different sales, business development, and operational roles of increasing responsibility.
Prior to joining Indivumed, Hans was at BARC Global Central laboratory, a GCLP laboratory that supports pharmaceutical and biotechnology companies with analytical and biomarker testing support for clinical trials. For many years he led a global team in charge of proposal development and contract management and helped secure large projects. Hans also worked in a business development role for DxS Genotyping, a small biotech company active in the field of personalized medicine, later acquired by Qiagen. Prior to this, he held different sales positions at Covance and GE Healthcare.
Hans holds a master's degree in Biochemistry from Utrecht University (The Netherlands) and a Ph.D in Medical Science from the Catholic University Leuven (Belgium).
Kevin Sullivan has over 30 years’ experience in the Life Sciences with an emphasis on marketing and direct sales of products and services, breaking new technological ground in the pharmaceutical drug discovery and development industry.
Before joining Indivumed, he spent 11 years at Fisher Scientific, now Thermo Fisher, in direct sales, technical marketing, and international distribution. He helped expand Fisher to manufacturing diagnostics products in Japan; and sourced, developed, and launched several OEM clinical product lines into the emerging markets of South America and the Pacific Rim. After Fisher, Kevin led sales and international distribution in two start-up companies based in Pittsburgh, PA, before joining Indivumed in 2005.
Kevin holds a B.S. in Chemistry from the University of Maryland, College Park, following the completion of which he pursued post-graduate studies in physical chemistry at the University of South Carolina.
Leonidas D. Leondaridis brings 33 years of IT medical engineering and biobanking experience in cancer research and clinical care between industry, government, academia, and health care systems to Indivumed.
Prior to joining Indivumed, Leonidas served as a systems administrator with Lombardi Comprehensive Cancer Center at Georgetown University, one of the leaders in cancer research and health care systems, where he successfully supported critical cancer research projects and helped establish the Lombardi Cancer Tissue Shared Resource Center, as well as helping with the development of the GDoc Bioinformatics Data Integration platform. Leonidas also served as an IT systems administrator at the LabCorp corporation in Herndon VA, where he managed critical laboratory systems and laboratory interface engines with a daily capacity of 21,000 sample processing.
Leonidas has almost 25 years experience as a consultant at the National Institute of Health in Bethesda, MD, working alongside top researchers, supporting cancer research, animal modeling, and biorepository. Leonidas worked as an IT research associate at the George Washington Hospital and helped develop a new interface engine, as well as supporting the setup and deployment of new hospital systems such as IDX, Pyxis, and Cerner. Leonidas also served as research associate at the George Washington University and helped develop and set up the Cancer Center Network System.
He holds a bachelor’s degree in science, as well as a master’s degree in medical engineering from George Washington University.
Dr. Nina Gabelia has almost a decade of experience running Indivumed biobanking operations in the United States, where under her supervision, Indivumed has grown its clinical network for biobanking and laboratory services among partner health system networks. With a background in clinical medicine, she brings to Indivumed her expertise on health project management, international health and bilateral relations, clinical trials, IRB and human subject related matters, research, and development.
Previously, Nina served as the director, co-investigator, and laboratory manager for the Indivumed Biorepository and Human Tissue Collection operation at the Georgetown Lombardi Cancer Center. Her focus was on establishing a state-of-the-art tissue biorepository for the development of the tailored, individualized therapies to cure cancer at LCCC/GUMC, using cutting-edge technology for the human tissue acquisition, preservation, and retrieval provided through the technology transfer and know-how of the German biotech company Indivumed.
Prior to joining Indivumed, she worked at the U.S. Department of Health and Human Services (HHS) as a senior international health officer at the Office of Global Health Affairs and the Office of Secretary, supporting two HHS Secretaries and their immediate cabinet members in strengthening international partnerships in medicine and biomedical research and developing individualized treatment approaches. Nina also worked at Fred Hutchinson Cancer Center on launching the Breast Cancer Global Initiative and managed its international portfolio. In addition, she worked on issues related to research on human subjects in the NIH Director’s Office of Extramural Research. Prior to this, she worked as the assistant director for scientific research at the Georgian National Center for Cancer Diagnostics.
She earned her Medical Degree from the Aieti Medical School in Tbilisi, Georgia in 2001. Later she completed NIH/Fogarty Fellowship and earned a Master of Public Health degree from the Rollins School of Public Health, Emory University in Atlanta, Georgia in May 2004.
PD Dr. Kerstin David brings to Indivumed more than 20 years of research experience, primarily in the field of cancer research. She holds knowledge in a broad spectrum of technologies in Proteomics, Cell Biology, and Genomics.
Kerstin gained working experience in the field of hematology-oncology as a certified medical technologist before she studied biology. She received her Ph.D. in Biochemistry at the University of Hamburg. Kerstin continued her research activities as assistant professor of the Department of Biochemistry and Molecular Biology at the University of Hamburg. Kerstin also served as assistant professor at the Cancer Research Center, University of Manoa, Hawaii. Her research has been focused on cancer research throughout the entirety of her career. Kerstin had been especially recognized for her research on Neuroblastoma and honored for the discovery of “Natural antibodies cytotoxic against Neuroblastoma cells.” She was a principal investigator on several grants and has authored multiple peer-reviewed scientific publications in journals and textbooks.
She is still active as a teacher (Privatdozent) at the University of Hamburg, as well as a supervisor for Bachelor, Master and Ph.D. students.
In 2002 Kerstin became a member of the start-up team at Indivumed. She built up and headed the Histopathology department, as well as research and services at Indivumed.
Kerstin holds a Ph.D. in Biochemistry as well as a habilitation (venia legendi) in Biochemistry and Molecular Biology from the University of Hamburg.
Dr. Bernd Gromoll is a surgical pathologist/histopathologist with more than 25 years experience in daily, routine pathology.
Before joining Indivumed, he worked in different hospitals and private pathological institutes. His primary working experience is in the pathology of the gastrointestinal tract, general surgical pathology, breast pathology, gynecological cytology, and dermatopathology.
Bernd studied at the University of Greifswald, has a Medical Approbation, and holds a Dr. med. degree, having completed his dissertation in Clinical Biochemistry.
Dr. Philipp Uhlig is a scientist with long-term experience in protein biochemistry and immunohistochemistry, which he utilizes to support clients with respect to their needs in preclinical and clinical research.
Before joining Indivumed, Philipp was an academic researcher in the field of connective tissue research. He has expert knowledge in protein biochemistry, immunohistochemistry, and immune electron microscopy. With his comprehensive experience in validating research antibodies, he has led the immunohistochemistry department of Indivumed for more than 5 years. His growing team is highly experienced in developing and validating IHC assays to perform biomarker analyses in preclinical and clinical research.
Philipp is a certificated biologist (Diplom) and holds a Ph.D. degree in science (Dr. rer. nat.) from the University of Münster, Germany (Westfälische Wilhelms-Universität).
Antje Schmitt has almost 20 years of experience working in human resources.
Since 2001, Antje has worked in an international corporate environment. Before joining Indivumed in July 2017, she worked as an HR business partner, holding various management positions at a number of service and technology companies. She spent the last six years working as a senior HR manager at a French technology group’s Hamburg office, where she was primarily involved in the aviation industry.
Anje is a qualified business economist, specializing in personnel and labor law. She completed her studies in economics and social sciences at the University of Hamburg.
Nils Schumacher brings over 20 years of in-house legal experience to Indivumed, with a particular emphasis on contract, corporate and IP law.
Nils’ diverse work experience includes having served as a legal advisor, HR director and corporate secretary. Prior to joining Indivumed in 2017, Nils worked at a venture capital and private equity-financed multinational start-up, for an internationally operating developer and distributor of software solutions and IT media, for an IT business consultancy and for a US law firm.
As a qualified lawyer (diploma from Friedrich-Alexander-University Erlangen and Bavarian state examinations) and an admitted solicitor, Nils holds a master’s degree in business mediation from IUKB Sion, as well as a diploma in business administration from Hagen University.
Indivumed has established close and long-standing partnerships with leading hospitals and clinics in Europe, North America, and Asia. The collaboration with these institutions is the basis for maintaining and expanding Indivumed’s high-quality biobank with biospecimen of all major malignant tumor entities. Indivumed is continually expanding its clinical network in order to provide even better biobank products and services for oncological drug discovery and development programs.